July 20, 2021 – Albireo Pharma’s BylvayTM (odevixibat) has become the first drug approved by the U.S. FDA
to treat pruritus in individuals who are at least three months
July 20, 2021 – The U.S. FDA has approved a new indication for Octagam® 10% [immune globulin intravenous (human)] to treat adult dermatomyositis, a rare inflammatory
July 16, 2021 – The U.S. FDA has approved VaxneuvanceTM (pneumococcal 15-valent conjugate vaccine –
Merck) for active immunization to prevent invasive disease
July 16, 2021 – The U.S. FDA has approved Sanofi’s fexinidazole tablets to treat both stages of sleeping
sickness (human African trypanosomiasis, or HAT) caused by Trypanosoma